Open

Biomarker analysis of breast cancer patients receiving immunotherapy

The purpose if the study is to test tumor tissue from breast cancer patients that has already been collected. Patients who have been or are being considered for immunotherapy will be eligible for this study. The goal of this study is to understand how immunotherapy works.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

United States (Nationwide)

What will be asked of you

If you choose to take part in this study, some tumor tissue previously removed for standard of care purposes will be used for research. This study does not require a new biopsy. Additionally, the study team will periodically examine your clinical records to assess your response to the immunotherapy and any side-effects from the therapy.

In-person visits:
5-15

Phone or online visits:
5-15

Total length of participation:
2 years

Looking for Specific Volunteers

Able to participate:

You have metastatic or early-stage breast cancer.
You have been treated or are currently being treated with immunotherapy.
You have frozen tumor and/or normal tissue available for additional testing.

Not eligible if:

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Yara Abdou
LCCC - Clinical Trials

Study Type

Clinical or Medical
Observational

Study Topics

Cancer (Breast)

IRB Number

24-0444

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.